N
Nelly Robillard
Researcher at French Institute of Health and Medical Research
Publications - 101
Citations - 5213
Nelly Robillard is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple myeloma & Minimal residual disease. The author has an hindex of 37, co-authored 101 publications receiving 4787 citations. Previous affiliations of Nelly Robillard include University of Nantes.
Papers
More filters
Journal ArticleDOI
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.
Soraya Wuilleme-Toumi,Nelly Robillard,P. Gomez,Philippe Moreau,S. Le Gouill,Hervé Avet-Loiseau,J-L Harousseau,Martine Amiot,Régis Bataille +8 more
TL;DR: Mcl-1, which has been shown to be essential for the survival of human myeloma cells in vitro, is overexpressed in vivo in MM in relation with relapse and shorter survival, and represents a potential therapeutical target in MM.
Journal ArticleDOI
Reproducible Obtaining of Human Myeloma Cell Lines as a Model for Tumor Stem Cell Study in Human Multiple Myeloma
Xue Guang Zhang,Jean Philippe Gaillard,Nelly Robillard,Zhao-Yang Lu,Zong-Jiang Gu,Michel Jourdan,Jean-Michel Boiron,Régis Bataille,Bernard Klein +8 more
TL;DR: The possibility of obtaining malignant plasma cell lines reproducibly from each patient with extramedullary proliferation offers a unique tool for studying the phenotype and abnormalities of the still unidentified tumor stem cell in this disease.
Journal ArticleDOI
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot,Valérie Lauwers-Cances,Jill Corre,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Thomas D. Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Hervé Avet-Loiseau,Nikhil C. Munshi +42 more
TL;DR: The findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Journal ArticleDOI
Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance.
Stéphanie Louis,Cécile Braudeau,Magali Giral,Alexandre Dupont,Frédérique Moizant,Nelly Robillard,Anne Moreau,Jean-Paul Soulillou,Sophie Brouard +8 more
TL;DR: Data show that chronic rejection is associated with a decrease in CD25hiCD4+T cells and FOXP3 transcripts, suggesting that clinically “operational tolerance” may be due to a maintained phenomenon of natural tolerance that is lacking in patients with chronic rejection.
Journal ArticleDOI
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
Régis Bataille,Gaëtan Jego,Nelly Robillard,Sophie Barillé-Nion,Jean-Luc Harousseau,Philippe Moreau,Martine Amiot,Catherine Pellat-Deceunynck +7 more
TL;DR: This review presents data from normal PC up to human myeloma cell lines in order to define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and identify new therapeutic targets.